[go: up one dir, main page]

MX2018001055A - Promotores para mejorar la expresion en poxvirus. - Google Patents

Promotores para mejorar la expresion en poxvirus.

Info

Publication number
MX2018001055A
MX2018001055A MX2018001055A MX2018001055A MX2018001055A MX 2018001055 A MX2018001055 A MX 2018001055A MX 2018001055 A MX2018001055 A MX 2018001055A MX 2018001055 A MX2018001055 A MX 2018001055A MX 2018001055 A MX2018001055 A MX 2018001055A
Authority
MX
Mexico
Prior art keywords
poxvirus
promoters
expression
improve expression
improve
Prior art date
Application number
MX2018001055A
Other languages
English (en)
Other versions
MX389312B (es
Inventor
Delcayre Alain
Li Zengji
Rountree Ryan
Original Assignee
Bavarian Nordic As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bavarian Nordic As filed Critical Bavarian Nordic As
Publication of MX2018001055A publication Critical patent/MX2018001055A/es
Publication of MX389312B publication Critical patent/MX389312B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6897—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids involving reporter genes operably linked to promoters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/863—Poxviral vectors, e.g. entomopoxvirus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/15—Vector systems having a special element relevant for transcription chimeric enhancer/promoter combination
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Analytical Chemistry (AREA)
  • Plant Pathology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente invención hace referencia a uno o más promotores y/o casetes de expresión que pueden usarse para mejorar la expresión de un gen heterólogo, tal como Brachury. En particular, el o los promotores y/o casetes de expresión mejoran la expresión de genes heterólogos como parte de un vector viral, tal como un poxvirus.
MX2018001055A 2015-07-31 2016-07-28 Promotores para mejorar la expresion en poxvirus. MX389312B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562199681P 2015-07-31 2015-07-31
PCT/IB2016/001183 WO2017021776A1 (en) 2015-07-31 2016-07-28 Promoters for enhancing expression in poxviruses

Publications (2)

Publication Number Publication Date
MX2018001055A true MX2018001055A (es) 2018-05-17
MX389312B MX389312B (es) 2025-03-20

Family

ID=57068152

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018001055A MX389312B (es) 2015-07-31 2016-07-28 Promotores para mejorar la expresion en poxvirus.

Country Status (15)

Country Link
US (1) US11753652B2 (es)
EP (1) EP3329016B1 (es)
JP (1) JP6851364B2 (es)
KR (1) KR102565284B1 (es)
CN (1) CN107922981B (es)
AU (1) AU2016303378B2 (es)
CA (1) CA2990549A1 (es)
DK (1) DK3329016T3 (es)
ES (1) ES2901468T3 (es)
IL (1) IL256869B (es)
MX (1) MX389312B (es)
RU (1) RU2753884C2 (es)
SG (1) SG10202000447YA (es)
WO (1) WO2017021776A1 (es)
ZA (1) ZA201800104B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102754876B1 (ko) 2017-08-24 2025-01-13 버베리안 노딕 에이/에스 재조합 mva 및 항체의 정맥내 투여에 의한 암 치료를 위한 병용 요법
MX2020006471A (es) 2017-12-19 2020-09-22 Janssen Sciences Ireland Unlimited Co Metodos y composiciones para inducir una respuesta inmune contra el virus de hepatitis b (hbv).
JP7555334B2 (ja) 2018-10-05 2024-09-24 バヴァリアン・ノルディック・アクティーゼルスカブ 組み換えｍｖａ、及び免疫チェックポイントアンタゴニストまたは免疫チェックポイントアゴニストの静脈内投与によって、がんを治療する併用療法
JP7625518B2 (ja) 2018-11-20 2025-02-03 バヴァリアン・ノルディック・アクティーゼルスカブ ４－１ｂｂｌ（ｃｄ１３７ｌ）及び／またはｃｄ４０ｌをコードする組み換えｍｖａの腫瘍内及び／または静脈内投与によって、がんを治療する療法
KR20220106775A (ko) 2019-11-20 2022-07-29 버베리안 노딕 에이/에스 암 치료를 위한 종양내 및/또는 정맥내 투여를 위한 재조합 mva 바이러스
EP4452305A1 (en) 2021-12-23 2024-10-30 Bavarian Nordic A/S Recombinant mva viruses for intraperitoneal administration for treating cancer
CA3240596A1 (en) 2021-12-23 2023-06-29 Cigdem ATAY LANGBEIN Therapy for modulating immune response with recombinant mva encoding il-12
AU2024208643A1 (en) 2023-01-12 2025-06-26 Bavarian Nordic A/S RECOMBINANT MODIFIED saRNA (VRP) FOR CANCER VACCINE

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5766598A (en) 1991-03-07 1998-06-16 Virogenetics Corporation Recombinant attenuated ALVAC canarypoxvirus expression vectors containing heterologous DNA segments encoding lentiviral gene products
EP1380651A2 (en) * 1991-08-26 2004-01-14 Baxter Healthcare S.A. Recombinant fowlpox virus with intact FPV-tk-gene
EP2112225A1 (en) 1996-07-25 2009-10-28 The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services Recombinant pox virus for immunization against tumor-associated antigens
RU2180352C2 (ru) 1999-11-24 2002-03-10 Государственный научный центр вирусологии и биотехнологии "Вектор" ФРАГМЕНТ ГЕНОМА ВИРУСА ОСПЫ КУР ШТАММА "К", СОДЕРЖАЩИЙ ГЕН ТИМИДИНКИНАЗЫ, РЕКОМБИНАНТНЫЕ ПЛАЗМИДНЫЕ ДНК pTK1FPV И pTK2FPV, СОДЕРЖАЩИЕ ЭТУ ПОСЛЕДОВАТЕЛЬНОСТЬ, И РЕКОМБИНАНТНАЯ ПЛАЗМИДНАЯ ДНК pINTFPV1, ОБЛАДАЮЩАЯ СПОСОБНОСТЬЮ ИНТЕГРИРОВАТЬСЯ В ГЕНОМ ВИРУСА ОСПЫ КУР
EP1601333B1 (en) * 2003-02-20 2013-01-23 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by the Secretary, Department of Health and Human Services Novel insertion sites in pox vectors
JP2007508327A (ja) * 2003-10-15 2007-04-05 バイラックス・ディベロップメント・プロプライエタリー・リミテッド レトロウィルス（ｅｇｈｉｖ）およびサイトカインをコードするポックスウィルスベクター
EP2918598B1 (en) * 2007-02-28 2019-01-30 The Govt. Of U.S.A. As Represented By The Secretary Of The Department Of Health And Human Services Brachyury polypeptides and methods for use
CN101775410B (zh) * 2009-01-09 2011-11-16 中国人民解放军军事医学科学院军事兽医研究所 一种鸡痘病毒载体穿梭质粒及其应用
ES2660597T3 (es) * 2009-04-17 2018-03-23 Globeimmune, Inc. Composiciones inmunoterápicas de combinación contra el cáncer y métodos
CN102321637A (zh) 2011-09-09 2012-01-18 中国人民解放军军事医学科学院军事兽医研究所 中国鸡痘病毒282e4弱毒株全基因组序列及其应用
WO2014043535A1 (en) * 2012-09-14 2014-03-20 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Compositions for the treatment of cancer

Also Published As

Publication number Publication date
ES2901468T3 (es) 2022-03-22
EP3329016A1 (en) 2018-06-06
CN107922981A (zh) 2018-04-17
BR112018002172A8 (pt) 2024-02-15
RU2018106643A3 (es) 2020-01-30
SG10202000447YA (en) 2020-03-30
KR20180033498A (ko) 2018-04-03
KR102565284B1 (ko) 2023-08-08
EP3329016B1 (en) 2021-10-20
CA2990549A1 (en) 2017-02-09
RU2018106643A (ru) 2019-08-28
IL256869A (en) 2018-03-29
US20180216134A1 (en) 2018-08-02
AU2016303378B2 (en) 2021-12-23
NZ738713A (en) 2024-11-29
DK3329016T3 (da) 2022-01-10
CN107922981B (zh) 2022-02-25
BR112018002172A2 (pt) 2018-09-18
IL256869B (en) 2022-07-01
JP2018521651A (ja) 2018-08-09
ZA201800104B (en) 2022-04-28
US11753652B2 (en) 2023-09-12
RU2753884C2 (ru) 2021-08-24
HK1254405A1 (en) 2019-07-19
MX389312B (es) 2025-03-20
JP6851364B2 (ja) 2021-03-31
WO2017021776A1 (en) 2017-02-09
AU2016303378A1 (en) 2018-01-25

Similar Documents

Publication Publication Date Title
MX2018001055A (es) Promotores para mejorar la expresion en poxvirus.
BR112018002600A2 (pt) células para imunoterapia modificadas para direcionamento ao antígeno cd38 e para inativação do gene cd38
MX2017005958A (es) Composiciones de acido ribonucleico de interferencia (arni) contra el virus de la hepatitis b (hbv) y metodos de uso de estas.
MX382223B (es) Regulacion de expresion genica mediada por nucleasa.
UY35385A (es) ?métodos y composiciones para el control de malezas?.
MX2019009361A (es) Composiciones y metodos para el tratamiento de hemoglobinopatias.
MX2019011040A (es) Composiciones y metodos para potenciar la expresion genica.
MX378913B (es) Células para inmunoterapia diseñadas para dirigir antígeno presente tanto en células inmunes y células patológicas.
MX2019008359A (es) Cadena j modificada.
AR095232A1 (es) Métodos y composiciones para el control de malezas
MX384795B (es) Vectores que comprenden secuencias de polinucleotidos rellenadoras/de relleno y metodos de uso.
DOP2017000124A (es) Agonistas parciales del receptor de insulina
CR20140538A (es) Métodos y composiciones para la modificación de adn objetivo dirigida por arn y para la modificación de la transcripción dirigida por arn
MX368723B (es) Composiciones y metodos para inhibir la expresion del gen alas1.
AR103553A1 (es) Promotor y usos del mismo
CL2018000164A1 (es) Vector recombinante del virus orf.
MX2017006283A (es) Peptidos macrociclicos utiles como inmunomoduladores.
MX387665B (es) Péptidos, complejos, moléculas de carga y nanopartículas que contienen los mismos.
NZ735660A (en) Thiolene-based compositions with extended pot life
GT201600066A (es) Composiciones y métodos para inhibir la expresión del gen alas1
MX377211B (es) Composiciones terapéuticas para usarse en el tratamiento del cáncer.
MX2016013849A (es) Un factor de secrecion de proteinas con alta eficacia secretora y un vector de expresion que lo comprende.
MX2017008587A (es) Mirna natural para controlar la expresion de gen y uso del mismo.
MX2018004063A (es) Secuencias recombinantes de cromosoma b de maíz y sus usos.
MX2018004542A (es) Neoepítopos virales y sus usos.